Clinical and pharmacokinetic factors affecting response to phenelzine
Sixty patients, 30 with depressive neurosis, 15 with anxiety neurosis and 15 with phobic anxiety states, were treated with the monoamine oxidase inhibitor, phenelzine, in two different dosage schedules for four weeks. All patients received an initial dose of 15 mg daily, increasing to 30 mg daily between the third and seventh day, but subsequently, using double-blind procedure, one group tooke the commonly prescribed dose of 45 mg daily and the other took 90 mg daily. Acetylator status was independently determined before the start of treatment. Each diagnostic group showed a similar response to treatment, but patients taking the higher dose improved significantly more than those taking normal dosage, and the rate of improvement, measured by weekly self-ratings, was also more rapid with higher dosage. Acetylator status did not affect clinical response. The results suggest that dosage is more important in determining clinical response to phenelzine in neurotic disorder than specific diagnosis or acetylator status.
The influence of acetylator phenotype on the outcome of treatment with phenelzine, in a clinical trial
The relationship between acetylator status and inhibition of monoamine oxidase, excretion of free drug and antidepressant response in depressed patients on phenelzine
The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive -anxiety states. A controlled clinical trial
The prognosis of affective disorders: the differentiation of anxiety states from depressive illnesses
Assessment of the severity of primary depressive illness. Wakefield self-assessment depression inventory
The natural history of affective disorders. I. Symptoms of 72 patients at the time of index hospital admission
REPORT ON ANTIBIOTIC SENSITIVITY TEST TRIAL ORGANIZED BY THE BACTERIOLOGY COMMITTEE OF THE ASSOCIATION OF CLINICAL PATHOLOGISTS
Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans
Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review
Clinical effects of abrupt withdrawal from tri-cyclic antidepressants and monoamine oxidase inhibitors after long-term treatment
Atypical symptoms in hospitalised patients with major depressive episode: frequency, clinical characteristics, and internal validity
Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.